News from neurosigma, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 11, 2021, 23:00 ET NeuroSigma Continues to Build a Substantial Global Bioelectronics Patent Portfolio

NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing trigeminal nerve stimulation (TNS) technology to treat...

Jan 22, 2021, 08:53 ET NeuroSigma Successfully Obtains HCPCS Codes from CMS for the Monarch eTNS System

NeuroSigma, Inc., a Los Angeles-based bioelectronics company that is commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Dec 17, 2020, 22:00 ET NeuroSigma's Monarch eTNS for Pediatric ADHD Featured in MD+DI's List of the 10 Wearable Medical Devices that Redefined Healthcare

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Oct 21, 2020, 20:00 ET NeuroSigma Announces Publication of ADHD Clinical Trial Data That Provide Additional eTNS Mechanism of Action

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Jun 24, 2020, 08:55 ET NeuroSigma Congratulates Spanish Team for their Results in Randomized Controlled Trial of eTNS in Drug Resistant Epilepsy

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Oct 17, 2019, 08:50 ET Teijin and NeuroSigma Enter into Exclusive License Agreement

Teijin Limited (Teijin) and NeuroSigma, Inc. (NeuroSigma), a Los Angeles-based bioelectronics company focused on developing Trigeminal Nerve...

Oct 08, 2019, 08:50 ET NeuroSigma Announces Partnership with Quick Care Pharmacy for Sales and Distribution of the Monarch eTNS System in the US

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on developing Trigeminal Nerve Stimulation (TNS) technology for treating...

Jun 27, 2019, 08:47 ET NeuroSigma Announces Presentation of Clinical Trial Data Showing Increased Brain Activity and Improved Cognition in Children with ADHD Treated with eTNS

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Apr 23, 2019, 23:02 ET NeuroSigma Announces FDA Clearance of Monarch eTNS System as First Non-Drug Treatment for Pediatric ADHD

NeuroSigma, Inc., a Los Angeles-based bioelectronics company focused on commercializing Trigeminal Nerve Stimulation (TNS) technology for treating...

Dec 10, 2015, 07:00 ET Preliminary Results Utilizing NeuroSigma's Monarch eTNS System for the Treatment of Traumatic Brain Injury Presented at the North American Neuromodulation Society Annual Meeting

NeuroSigma, Inc. (NeuroSigma), today announced positive preliminary findings from a clinical study using non-invasive external Trigeminal Nerve...

Nov 16, 2015, 05:00 ET NeuroSigma's Monarch eTNS System Receives CE Mark Approval for ADHD

NeuroSigma®, Inc. (NeuroSigma) today announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for...

May 04, 2015, 07:00 ET NeuroSigma's Thin Film Nitinol Flow Diverting Stent Results Presented at the American Society of Neuroradiology Meeting

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company, today announced that results of an animal study of its Thin Film Nitinol...

Nov 17, 2014, 07:00 ET NeuroSigma Announces Top-Line Findings of UCLA Phase II Clinical Trial of eTNS for the Treatment of Depression

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the ...

Nov 03, 2014, 07:00 ET NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS)

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS system for the ...

Oct 15, 2014, 07:00 ET NeuroSigma and the U.S. Veterans Administration (VA) Enter into Cooperative Research and Development Agreement (CRADA)

NeuroSigma®, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the ...

Aug 26, 2014, 06:45 ET NeuroSigma, Inc. Files Registration Statement for Proposed Initial Public Offering

NeuroSigma, Inc., a Los Angeles-based life sciences company established to develop bioelectronic technologies, today announced that it has filed a...

Aug 25, 2014, 07:00 ET U.S. Army Funds Phase II Clinical Trial at UCLA for the Treatment of PTSD with the NeuroSigma eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Jul 09, 2014, 07:00 ET NIH Funds Phase 2 Clinical Trial at UCLA for the Treatment of ADHD with NeuroSigma's eTNS System

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Jul 08, 2014, 07:00 ET Advances in Trigeminal Nerve Stimulation Featured at European Congress on Epileptology in Stockholm, Sweden

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Jun 03, 2014, 07:00 ET Leading UCLA Physician Dr. Ian Cook Joins NeuroSigma As Chief Medical Officer and Senior Vice President

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Apr 01, 2014, 07:00 ET NeuroSigma Receives Approval from Australian Therapeutic Goods Administration to Market its Monarch™ eTNS™ System for the Adjunctive Treatment of Drug-Resistant Epilepsy

NeuroSigma, Inc., a California-based life-sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for the treatment...

Feb 25, 2014, 07:00 ET David Hayes, Former Partner at O'Melveny & Myers LLP and Haynes and Boone LLP, Joins NeuroSigma As Chief Administrative Officer, General Counsel and Sr. Vice President

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Feb 11, 2014, 06:00 ET Former Amgen Finance Executive Carl Adams Joins NeuroSigma As Vice President and Controller

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Jan 27, 2014, 06:00 ET Former Allergan Marketing Executive Gregory F. Brooks Joins NeuroSigma As Senior VP and Chief Commercial Officer

NeuroSigma, Inc. (NeuroSigma), a California-based life sciences company focused on commercialization of its non-invasive Monarch™ eTNS™ System for...

Jul 29, 2013, 08:00 ET NeuroSigma Announces FDA Approval to Commence Phase III Trial

NeuroSigma, Inc., today announced conditional approval by the U.S. Food and Drug Administration (FDA) of its Investigational Device Exemption (IDE)...